Ace Pharmaceuticals strengthens shareholders base

13 January 2021

Zeewolde, 8 January 2021 – Ace Pharmaceuticals (Ace), a specialized pharmaceutical company in medical need medicines, strengthens its shareholder base with the accession of Gilde Buy-Out and Gilde Healthcare as of January 1st 2021. Attracting these investors specialized in the medical sector is an important step in realizing Ace’s ambition to further strengthen its position as an independent Dutch pharmaceutical company.

Ace ambitiously responds to a number of important trends in pharmaceutical healthcare. Director Jan Verwaal: “Steps in the supply chain are organized close to home again to ensure the availability of crucial raw materials and medicines for the Netherlands and Europe, independently of (distant) foreign countries. In addition, we can respond to important ‘drug-rediscovery’ and help reduce increasing drug shortages.”

Director Jan Willem Popma: “The COVID-19 pandemic has clearly demonstrated the challenges and gaps in our sector for European countries. It makes our mission to make and keep scarce medicines available more relevant than ever. We want to respond even stronger to these challenges by growing our presence in Europe both autonomously and through acquisitions. With the capital, know-how and the broad (international) network of Gilde Buy-out, Gilde Healthcare, and our existing investor Quadrum Capital, we can do so in a socially responsible and financially sound manner.”

The existing management team will continue to manage Ace, led by executives Jan Willem Popma and Jan Verwaal. They will remain a major shareholder next to Quadrum Capital.

About Ace Pharmaceuticals
As an independent Dutch pharmaceutical company, Ace Pharmaceuticals has been focusing on the development, production and distribution of licensed and unlicensed medicines since 1990. With its activities, Ace meets an essential social need; making and keeping scarce medication available for people for whom it is essential (through national named-patient programs included). Since January 2020 Ace also supplies (custom) pharmaceutical compounding products through Ace Compounding and Ace Apotheek (registered as pharmacy in the Netherlands). The strong growth in recent years has led to the construction of a new own production facility located at the site of the head office in Zeewolde, now employing 150 persons.

About Gilde Healthcare and Gilde Buy-Out
Gilde Healthcare is a specialized, independent European healthcare investor managing €1.4 billion. Through various funds Gilde Healthcare participates in profitable healthcare companies, including healthcare providers, medical product suppliers, pharmaceutical companies and service providers, with a focus on the Benelux and German-speaking countries. It also focuses on fast-growing innovative medical technology and pharmaceutical companies based in Europe and North America.

Gilde Buy Out Partners is a leading mid-market investment company in Europe that focuses on investments in growth companies with its headquarters in the Benelux and German-speaking countries. Gilde Buy Out Partners has more than €3.0 billion of Assets under management and has offices in Utrecht, Brussels, Frankfurt and Zurich. Since its start in 1982, Gilde Buy Out Partners has invested in more than 250 companies to realize their growth ambitions.

About Quadrum Capital
As a committed investment company, Quadrum Capital focuses on responsibly helping companies realize their growth ambitions. The contribution of high-quality management experience, a keen vision, network, financial strength and focus on strategy and management ensure that their approach produces results. Quadrum Capital is characterized by strong regional roots, entrepreneurial mentality and no-nonsense approach and since its inception in 2012 has built up a broad portfolio of holdings in various sectors, including in the medical & health domain.

Do you have any questions about this publication?
Please contact Ace Pharmaceuticals through our contact form.